• How Does Ketamine Work Differently from Most Mental Health Treatments?
• Why Do SSRIs and SNRIs Sometimes Fail?
• Why Do Suicide Interventions Fall Short?
• Evidence for PTSD, OCD, Anxiety & Substance Use 
• Can My Therapist Help Me Find a Ketamine Clinic?
• FAQs 

Ketamine is an evidence-based mental health treatment that has helped many people find relief from depression, anxiety, and post-traumatic stress disorder (PTSD), particularly when traditional care falls short. Ketamine works through a different brain pathway than standard antidepressants, helping rapidly improve mood and restore the brain’s ability to adapt and respond to treatment. Ketamine is not a guaranteed cure, and it is not appropriate for every person. However, it plays a meaningful role in recovery.

This article examines ketamine for mental health, including how it compares to antidepressants and why it can work when standard treatments fail. 

How Does Ketamine Work Differently from Most Mental Health Treatments?

Ketamine works through a different brain system than most antidepressants. Rather than primarily targeting serotonin neurotransmitters, ketamine acts on the glutamate system, which plays a central role in learning, memory, and emotional flexibility. This allows ketamine to influence mood and cognition through faster-acting pathways.

How Ketamine Affects the Brain

Ketamine infusions rapidly regulate glutamate signaling, which can help restore communication between brain regions (like mood, motivation, and regulation) that become disconnected during chronic depression, anxiety, or trauma. This process supports rapid synaptic repair (strengthening neural connections) and increases the brain’s capacity to adapt (neuroplasticity), often leading to symptom relief within hours or days.

Ketamine also produces mild dissociative or psychedelic-like effects during treatment, which may loosen rigid thinking patterns linked to depression, trauma, or suicidality. 

How Traditional Antidepressants Affect the Brain

Most standard antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), work by gradually increasing serotonin availability over time. SNRIs also increase norepinephrine, a neurotransmitter involved in energy, alertness, and stress response. 

By blocking the reuptake (reabsorption) of these chemicals, SSRIs and SNRIs allow them to remain active in the brain longer, which can help stabilize mood and reduce anxiety. This process can eventually relieve depression and support neural repair, but the process unfolds slowly over several weeks and requires sustained daily dosing.

Why Do SSRIs and SNRIs Sometimes Fail?

Typical antidepressants sometimes fail because they rely on limited biological pathways, act slowly, and may not adequately address chronic stress or trauma. Reports indicate that between 15% and 30% of depressive episodes fail to respond to adequate trials of two antidepressants, and 68% of individuals do not achieve remission after a first-line course of antidepressant treatment. 

Delayed onset

Research suggests that while serotonin levels change quickly after starting antidepressants, the downstream brain adaptations linked to mood improvement take much longer to occur. Standard antidepressants can take four to eight weeks to work, which can be discouraging or dangerous if symptoms are severe. 

Limited mechanisms

Most first-line antidepressants primarily work by adjusting serotonin levels in the brain. But depression is not just a “serotonin problem.” 

Research shows that depression can involve prolonged activation of the body’s stress system, which raises cortisol and keeps the body in a constant fight-or-flight state. It can also involve inflammation, oxidative stress (cellular strain caused by damaging molecules), and reduced support for healthy brain connections. Over time, these changes disrupt communication between brain regions that regulate mood, motivation, and resilience.

When multiple systems are affected, medications that target a single neurotransmitter may not fully address the broader biological picture.

Dosing and diagnosis issues

Clinicians often treat depression as a single condition, even though it can look very different from one person to the next. The National Institute of Mental Health recognizes that depression includes multiple subtypes shaped by factors like genetics, biology, and brain chemistry. Additionally, individuals metabolize medications differently. 

That variation helps explain why two people with the same diagnosis may respond very differently to the same SSRI. Current treatment approaches do not always account for that variability. Clinicians typically select antidepressants based on symptom presentation rather than biological testing, and treatment often becomes a process of trial and error.

Why Do Suicide Interventions Fall Short?

Some interventions, like SSRIs, fall short because they act too slowly to match the immediacy and intensity of suicidal crises. Others fail to relieve the symptoms contributing to despair.

First-line treatments for depression and mood disorders are designed to reduce symptoms linked to suicide over time. However, they cannot interrupt acute suicidal thinking in the moment it becomes dangerous. In some cases, SSRIs can even cause agitation, insomnia, or emotional blunting, which further complicates suicide risk in the short term.

Hospitalization and crisis stabilization are essential for suicide prevention. But these interventions focus on containment rather than rapid symptom relief. Many people are discharged once they are deemed “no longer imminently at risk,” even though distressing thoughts may remain largely unchanged.

Ketamine Effectiveness for TRD & Suicidality

Ketamine addresses many limitations of traditional antidepressants by acting quickly, reducing inflammation, and targeting broader brain network dysfunction linked to persistent depression and suicidal thinking. These mechanisms make ketamine highly effective for chronic depression and suicidal ideation. 

Treatment-resistant depression

Ketamine helps rapidly reduce symptoms in people with treatment-resistant depression (TRD). Research shows that up to 71% of TRD patients respond to ketamine by their sixth infusion. Depression reduction can last at least four weeks after a short series of IV ketamine infusions, or longer with an appropriate booster protocol and complementary psychotherapy. 

Suicidal ideation

Ketamine also provides critical support for patients experiencing acute suicidal ideation. Clinical trials show that ketamine treatment can rapidly reduce suicidal thoughts, sometimes within hours. Providers use this rapid effect to create a safety window that allows time for monitoring, therapy, and safety planning. This fast-acting intervention fills a major treatment gap that fails to address the immediacy of the crisis.

Evidence for PTSD, OCD, Anxiety & Substance Use 

Emerging clinical evidence indicates that ketamine can also help treat PTSD, OCD, anxiety disorders, and substance use disorders. Researchers must continue to conduct larger, placebo-controlled trials to confirm effectiveness, clarify the durability of response, and better identify who is most likely to benefit.

PTSD

Ketamine can produce measurable symptom improvements in PTSD, particularly when rigid cognitive loops dominate. According to a Cambridge review, ketamine reduced PTSD symptom severity scores by an average of 28.07 points and 14.07 points on clinician-administered scales. 

OCD

Obsessive-compulsive disorder is another condition in which ketamine can help disrupt harmful thought patterns and behavior loops. In the Cambridge review, ketamine produced a average reduction of 8.08 points on a Yale-Brown scale in people with OCD, suggesting meaningful reductions in compulsions and intrusive thoughts. 

Anxiety

Ketamine displays rapid anti-anxiety effects, thanks to its cognitive actions that can help a person feel calm, relaxed, and alter negative perceptions. Several studies encompassing over 1,200 adults showed that ketamine improved social functioning after a median follow-up time of 21 days.

Substance use disorders

Ketamine may support recovery across several substance use disorders. Clinical studies show that ketamine can reduce withdrawal symptoms, decrease cravings, and increase abstinence rates in alcohol use disorder, cocaine use disorder, and opioid use disorder. Researchers attribute its success to how ketamine helps the brain form new behavioral patterns and coping strategies, which may weaken conditioned responses to drug-related cues.

Can My Therapist Help Me Find a Ketamine Clinic?

Therapists can often help clients find care with a reputable ketamine clinic, even if the therapist is not a specialist in ketamine therapy. A therapist can also help their patient evaluate whether a clinic follows evidence-based protocols with proper screenings and ethical standards.

Some therapists actively refer patients, while others may need education or collaboration from the clinic’s care team. A good ketamine provider will welcome coordination, share treatment plans, and encourage patients to integrate the ketamine experience with ongoing therapy or coaching.

Ketamine for Mental Health at Avesta 

Avesta Ketamine and Wellness (Avesta), a DMV-area ketamine clinic, provides clinically supervised infusions and Spravato therapy as part of a comprehensive mental health treatment program for patients in Bethesda, DC, Columbia, Tysons, and Norfolk. Founder and Co-CEO, Dr. Ladan Eshkevari, intentionally designed Avesta around a patient-centered care model.

Avesta prioritizes patient safety through thorough clinical and psychological screening, individualized dosing strategies, and coordination with each patient’s therapists and prescribing providers. Avesta delivers ketamine treatment as a supportive component of a broader mental health plan—not as a standalone solution. This collaborative, integrated approach reflects current evidence-based best practices and a commitment to long-term patient wellbeing.

Schedule a free consultation with Avesta to learn whether ketamine therapy may help support your mental health recovery goals.

FAQs 

Is ketamine better than standard SSRIs & psychotherapy?

Ketamine is not universally better than SSRIs or psychotherapy. However, ketamine may provide meaningful relief for individuals with severe, time-sensitive, or treatment-resistant symptoms, particularly when other approaches have not worked.

Do I need to stop taking other medications if I do ketamine therapy?

Most patients do not need to stop their current medications before starting ketamine therapy. Reputable clinical teams review all prescriptions to ensure safety and may adjust certain medications if needed to optimize effectiveness.

How quickly does ketamine work compared to antidepressants?

Ketamine often produces noticeable changes within hours or days of treatment. Traditional antidepressants typically take several weeks to build up in the system before significant improvement occurs.

Is ketamine a last-resort treatment?

Ketamine is commonly used for treatment-resistant depression, but it is not strictly a last-resort option. In some cases, earlier intervention may be appropriate based on symptom severity and clinical judgment.

Who should not try ketamine therapy for mental health?

Ketamine may not be appropriate for individuals with uncontrolled high blood pressure, certain heart conditions, active psychosis, or specific risks. A thorough medical and psychological screening helps determine whether treatment is safe and appropriate.

How long do ketamine’s mental health benefits last?

Duration varies by person and by protocol. Some people feel relief for days to weeks after a single session, while a structured series followed by maintenance treatments can help some patients sustain benefits for months. Research on intranasal esketamine also shows that continued maintenance treatment can help reduce relapse risk over time.

What does a ketamine therapy protocol look like?

Clinicians administer ketamine through intravenous infusions or prescribe esketamine as a ketamine analog nasal spray. The ketamine therapy process typically begins with an induction phase that includes six to eight treatments delivered over two to three weeks, and then transitions to a personalized maintenance schedule.